Soluble TNF-α receptor 2 produced by alternative splicing is paradoxically associated with markers of liver injury

Clinical Immunology

Volumn 123, Issue 1, 2007, Pages 89-94

  Esteve, Eduardo ^a   Botas, Patricia ^b   Delgado, Elías ^b   López Bermejo, Abel ^a   Lainez, Begoña ^a   Engel, Pablo ^c   Ricart, Wifredo ^a   Fernández Real, Jose Manuel ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b Hospital de Asturias   (Spain)

^c Immunology Unit   (Spain)

Author keywords

Diabetes; ; Inflammation; Liver disease;

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; INSULIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALTERNATIVE RNA SPLICING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; LIVER FUNCTION; LIVER INJURY; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; ALANINE TRANSAMINASE; ALTERNATIVE SPLICING; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 33947108894     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.12.005     Document Type: Article

References (35)

1. Harrison S.A., and Bisceglie A.M. Advances in the understanding and treatment of non-alcoholic fatty liver disease. Drugs 63 (2003) 2379-2394
2. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 24 (2003) 278-301
3. Kugelmas M., Hill D., Vivian B., Marsano L., and McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 (2003) 413-419
4. Esteve E., Ricart W., and Fernandez-Real J.M. Dyslipidemia and inflammation: an evolutionary mechanism. Clin. Nutr. 24 (2005) 16-31
5. Berson A., De Beco V.D., Letterson P., Robin M., Moreau C., Kahwaji J.E., et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114 (1998) 764-774
6. Medina J., Fernandez-Salazar L.I., Garcia-Buey L., and Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 27 (2004) 2057-2066
7. Iimuro Y., Gallucci R.M., Luster M.I., Kono H., and Thurman N.G. Antibodies to tumor necrosis factor α in alcohol induced liver injury in mice. Hepatology 26 (1997) 1530-1537
8. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and George J. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology 40 (2004) 46-54
9. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., and deIasio R. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease. J. Clin. Endocrinol. Metab. 90 (2005) 3498-3504
10. Pagano C., Soardo G., Esposito W., Fallo F., Basan L., Donnini D., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 152 (2005) 113-118
11. Combs T.P., Berg A.H., Obici S., Scherer P.E., and Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108 (2001) 1875-1881
12. Rajala M.W., and Scherer P.E. The adipocyte: at the crossroads of energy homeostasis, inflammation and atherosclerosis. Endocrinology 144 (2003) 3765-3773
13. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 54 (2005) 117-121
14. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
15. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., and Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss and relationship to lipoprotein lipase. J. Clin. Invest. 95 (1995) 2111-2119
16. Fernández-Real J.M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47 (1998) 1757-1762
17. Straczkowski M., Kowalska I., Dzienis-Straczkowska S., Stepein A., Skibinska E., Szelachowska M., et al. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur. J. Endocrinol. 145 (2001) 273-280
18. Laínez B., Fernández-Real J.M., Romero X., Esplugues E., Ricart W., and Engel P. Identification and expression of a spliced variant that encodes human soluble TNF type 2 receptor. Int. Immunol. 16 (2003) 169-177
19. Botas-Cervero P., Delgado-Alvarez E., Castano-Fernández G., Diaz De Grenu C., Prieto-Santiago J., and Diaz-Cadorniga F.J. Prevalence of diabetes mellitus and glucose intolerance in the population aged 30 to 75 years in Asturias, Spain. Rev. Clin. Esp. 202 (2002) 421-429
20. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., and Cristianini G. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20 (1994) 1442-1449
21. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
22. Garcia-Monzon C., Martin-Perez E., Iacono O., Fernandez-Bermejo M., Majano P., Apolinario A., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J. Hepatol. 33 (2000) 716-724
23. Suzuki A., Angulo P., Lymp J., Sauver J., Muto A., Okada T., et al. Chronological development of elevated aminotransferases in nonalcoholic population. Hepatology 41 (2005) 64-71
24. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
25. Jeong S.K., Nam H.S., Rhee J.A., Shin J.H., Kim J.M., and Cho K.H. Metabolic syndrome and ALT: a community study in adult Koreans. In. J. Obes. Relat. Metab. Disord. 28 (2004) 1033-1038
26. Lopez-Bermejo A., Botas P., Funahashi T., Delgado E., Kihara S., Ricart W., et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin. Endocrinol. (Oxf) 60 (2004) 256-263
27. Targher G., Bertolini L., Scala L., Poli F., Zenari L., and Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin. Endocrinol. (Oxf) 61 (2004) 700-703
28. Fernandez-Real J.M., Lopez-Bermejo A., Broch M., Vendrell J., Richart C., and Ricart W. Circulating soluble CD14 monocyte receptor is associated with increased alanine aminotransferase. Clin. Chem. 50 (2004) 1456-1458
29. LopezBemejo A., Bosch M., Recasens M., Biarnes J., Esteve E., Casamitjana R., et al. Potential role of inteleukin-18 in liver disease associated with insulin resistance. Obes. Res. 13 (2005) 1925-1931
30. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., and Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48 (2001) 206-211
31. Fernandez-Real J.M., Strackowski, Lainez B., Chacon M.R., Kowalska I., Lopez-Bermejo A., et al. An alternative spliced variant of circulating soluble tumor necrosis factor-alpha receptor-2 is paradoxically associated with insulin action. Eur. J. Endocrinol. 154 (2006) 723-730
32. Fernandez-Real J.M., Botas-Cervero P., Lainez B., Ricart W., and Delgado E. An alternatively spliced soluble TNF-alpha receptor is associated with metabolic disorders. A replication study. Clin. Immunol. 121 (2006) 236-241
33. Festi D., Colecchia A., Sacco T., Bondi M., Roda E., and Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes. Rev. 5 (2004) 27-42
34. Vozarova B., Stefan N., Lindsay R.S., Saremi A., Pratley R.E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
35. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., and Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395